Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This open label study is to primarily evaluate reduction of itch and night-time scratch in
response to Crisaborole treatment in children with atopic dermatitis (AD). Participants, age
3 months to 5 years with symptomatic mild to moderate AD, along with their primary caregivers
will be recruited.
The goal of this study is to more fully evaluate the rapid onset of night-time itch and
scratch relief, as well as improvements in sleep following treatment with Crisaborole in
children with AD. the study will also assess the quality of life (QoL) and sleep within the
associated caregivers.